Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.
Background: Pyoderma gangrenosum is a serious cutaneous complication seen in approximately 1 % of patients with inflammatory bowel disease (IBD). Oral corticosteroids are the mainstay treatment, although the evidence supporting their use is weak.Aims: The purpose of this study was to investigate the...
| Publicado en: | Digestive Diseases & Sciences Vol. 58; no. 10; pp. 2949 - 2955 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Oct2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=109861459&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 109861459 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01632116 1VP jtl: Digestive Diseases & Sciences issn: 01632116 maglogo: N pubinfo: dt: Oct2013 vid: 58 iid: 10 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 109861459 NLM23828140 2012308588 10.1007/s10620-013-2762-2 NLM23828140 109861459 ppf: 2949 ppct: 6 formats: tig: atl: Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. aug: au: Argüelles-Arias, F Castro-Laria, L Lobatón, T Aguas-Peris, M Rojas-Feria, M Barreiro-de Acosta, M Soto-Escribano, P Calvo-Moya, M Ginard-Vicens, D Chaparro-Sánchez, M Hernández-Durán, M Castro-Senosiain, B Fernández-Villaverde, A García-Sánchez, V Domínguez-Muñoz, E Caunedo-Alvarez, A Herrerías-Gutiérrez, J M Caunedo-Álvarez, A affil: Hospital Virgen Macarena, Dr. Fedriani s/n, 41071, Seville, Spain, farguelles@telefonica.net. sug: subj: Colitis, Ulcerative Complications Crohn Disease Complications Inflammatory Bowel Diseases Complications Pyoderma Gangrenosum Drug Therapy Pyoderma Gangrenosum Pathology Administration, Oral Administration, Topical Adrenal Cortex Hormones Administration and Dosage Adrenal Cortex Hormones Therapeutic Use Adult Antibodies, Monoclonal Administration and Dosage Antibodies, Monoclonal Therapeutic Use Female Human Male Middle Age Pyoderma Gangrenosum Etiology Retrospective Design Spain Treatment Outcomes Adult: 19-44 years Middle Aged: 45-64 years Female Male ab: Background: Pyoderma gangrenosum is a serious cutaneous complication seen in approximately 1 % of patients with inflammatory bowel disease (IBD). Oral corticosteroids are the mainstay treatment, although the evidence supporting their use is weak.Aims: The purpose of this study was to investigate the characteristics of pyoderma gangrenosum associated with Crohn's disease or ulcerative colitis and which treatments are prescribed in Spanish clinical practice.Methods: In this retrospective, observational study, the medical records from all patients with IBD and a diagnosis of pyoderma gangrenosum attended by the gastroenterology departments of 12 Spanish hospitals were reviewed. Data on patient demographics and characteristics, underlying IBD and treatment, and pyoderma gangrenosum characteristics, treatment, and outcome were collected and analyzed.Results: The data from 67 patients were analyzed (41 [61.2 %] women, 41 [61.2 %] with Crohn's disease, 25 [37.3 %] with ulcerative colitis, and 1 [1.5 %] with indeterminate disease). The underlying disease was in remission in approximately one-third of patients at the time of presentation of pyoderma gangrenosum. Healing was achieved in all patients (in 3 without any systemic therapy). Oral corticosteroids were taken by 51 patients (76.1 %), almost always as first-line treatment, although definitive healing was attained in 19 (28.4 %). Biologic agents such as infliximab and adalimumab were taken by 31 patients (46.3 %) at some point (first-line in 6 patients [9.0 %]), with definitive healing in 29 patients (93.5 %).Conclusions: Oral corticosteroid therapy remains the most common treatment for pyoderma gangrenosum associated with inflammatory bowel disease. Biologic therapies such as infliximab and adalimumab should also be considered. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|